LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects

Documenti analoghi

• Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects
  di: Huan Song, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
  di: Assem el Baghdady, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
  di: Mohamed‐Eslam F Mohamed, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  di: Alessandra Cipriano, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults
  di: Nanyang Li, et al.
  Pubblicazione: (2025)